Pharmaceutical Strategies Group Releases Artemetrx State of Specialty Spend and Trend Report
Pharmaceutical Strategies Group (PSG) has released its 8th annual Artemetrx State of Specialty Spend and Trend report, sponsored by Walmart Specialty Pharmacy. The 2024 report reveals that specialty drug spend and trend increased by 14% in the past year, despite downward pressure from biosimilars and generic specialty drugs. Key findings include:
1. Claim utilization remains the leading driver of specialty drug trend, with cost per claim now playing a substantial role.
2. The population of specialty drug utilizers continues to grow.
3. Biosimilars are gaining traction, with notable increases in market share for Lucentis and Remicade alternatives.
4. Humira remains the top specialty drug by spend, while Skyrizi rose from sixth to third place.
The report offers insights for payers and plan sponsors, including forecasted trends and clinical perspectives on cell and gene therapies and Alzheimer's Disease drugs.
Il Pharmaceutical Strategies Group (PSG) ha pubblicato il suo ottavo rapporto annuale sullo stato della spesa e delle tendenze dei farmaci speciali Artemetrx, sponsorizzato da Walmart Specialty Pharmacy. Il rapporto del 2024 rivela che la spesa e le tendenze dei farmaci speciali sono aumentate del 14% nell'ultimo anno, nonostante la pressione al ribasso da biosimilari e farmaci speciali generici. Tra i risultati chiave troviamo:
1. L'utilizzo delle richieste rimane il principale motore delle tendenze dei farmaci speciali, con il costo per richiesta che gioca ora un ruolo sostanziale.
2. La popolazione di utilizzatori di farmaci speciali continua a crescere.
3. I biosimilari stanno guadagnando terreno, con aumenti significativi nella quota di mercato per le alternative a Lucentis e Remicade.
4. Humira rimane il principale farmaco speciale per spesa, mentre Skyrizi è passato dal sesto al terzo posto.
Il rapporto offre spunti per i pagatori e i patrocinatori dei piani, incluse tendenze previste e prospettive cliniche su terapie cellulari e geniche e farmaci per l'Alzheimer.
El Pharmaceutical Strategies Group (PSG) ha publicado su octavo informe anual sobre el estado del gasto y las tendencias de los medicamentos especializados Artemetrx, patrocinado por Walmart Specialty Pharmacy. El informe de 2024 revela que el gasto y las tendencias de los medicamentos especializados aumentaron en un 14% en el último año, a pesar de la presión a la baja de los biosimilares y medicamentos especializados genéricos. Los hallazgos clave incluyen:
1. La utilización de reclamaciones sigue siendo el principal impulsor de la tendencia de medicamentos especializados, con el costo por reclamación ahora desempeñando un papel importante.
2. La población de usuarios de medicamentos especializados continúa creciendo.
3. Los biosimilares están ganando terreno, con aumentos notables en la cuota de mercado de las alternativas a Lucentis y Remicade.
4. Humira sigue siendo el medicamento especializado principal por gasto, mientras que Skyrizi subió del sexto al tercer lugar.
El informe ofrece información para aseguradoras y patrocinadores de planes, incluidas tendencias pronosticadas y perspectivas clínicas sobre terapias celulares y génicas y medicamentos para la enfermedad de Alzheimer.
제약 전략 그룹(PSG)은 월마트 전문 약국이 후원하는 제8회 Artemetrx 전문 약물 지출 및 추세 보고서를 발표했습니다. 2024 보고서는 전문 약물 지출 및 추세가 지난 1년 동안 14% 증가했다고 밝혔으며, 이는 바이오시밀러 및 일반 전문 약물의 하방 압력에도 불구하고 이루어진 결과입니다. 주요 발견은 다음과 같습니다:
1. 청구 활용도가 여전히 전문 약물 추세의 주요 요인으로, 청구당 비용이 이제 상당한 역할을 하고 있습니다.
2. 전문 약물 사용자의 인구가 계속해서 증가하고 있습니다.
3. 바이오시밀러가 시장 점유율에서 루센티스 및 레미케이드 대체 약물에 대한 주목할 만한 증가를 보이며 주목받고 있습니다.
4. 후미라는 지출 기준의 최고 전문 약물로 남아 있으며, 스카이리지(Skyrizi)는 6위에서 3위로 상승했습니다.
이 보고서는 지불자와 계획 후원자를 위한 통찰력을 제공하며, 세포 및 유전자 요법 및 알츠하이머 질병 약물에 대한 예측 추세와 임상 관점을 포함합니다.
Le Pharmaceutical Strategies Group (PSG) a publié son huitième rapport annuel sur l'état de la dépense et des tendances en matière de médicaments spécialisés Artemetrx, parrainé par Walmart Specialty Pharmacy. Le rapport 2024 révèle que les dépenses et les tendances des médicaments spécialisés ont augmenté de 14% au cours de l'année écoulée, malgré la pression à la baisse exercée par les biosimilaires et les médicaments spécialisés génériques. Les principales conclusions comprennent :
1. L'utilisation des demandes reste le principal moteur de la tendance des médicaments spécialisés, le coût par demande jouant désormais un rôle important.
2. La population des utilisateurs de médicaments spécialisés continue de croître.
3. Les biosimilaires gagnent du terrain, avec des augmentations notables de la part de marché des alternatives à Lucentis et Remicade.
4. Humira reste le principal médicament spécialisé par les dépenses, tandis que Skyrizi est passé de la sixième à la troisième place.
Ce rapport offre des perspectives aux payeurs et aux sponsors de plans, y compris des tendances prévues et des perspectives cliniques sur les thérapies cellulaires et géniques ainsi que les médicaments contre la maladie d'Alzheimer.
Die Pharmaceutical Strategies Group (PSG) hat ihren achten Jahresbericht über den Stand der Ausgaben und Trends bei Spezialarzneimitteln Artemetrx veröffentlicht, der von Walmart Specialty Pharmacy gesponsert wird. Der Bericht für 2024 zeigt, dass die Ausgaben und Trends bei Spezialarzneimitteln im vergangenen Jahr um 14% gestiegen sind, trotz des Drucks durch Biosimilars und generische Spezialarzneimittel. Zu den wichtigsten Ergebnissen gehören:
1. Die Nutzung von Anträgen bleibt der Haupttreiber des Trends bei Spezialarzneimitteln, wobei die Kosten pro Antrag nun eine wesentliche Rolle spielen.
2. Die Anzahl der Nutzer von Spezialarzneimitteln wächst weiterhin.
3. Biosimilars gewinnen an Boden, mit bemerkenswerten Zuwächsen im Marktanteil für Alternativen zu Lucentis und Remicade.
4. Humira bleibt das teuerste Spezialarzneimittel, während Skyrizi von Platz sechs auf Platz drei aufgestiegen ist.
Der Bericht bietet Einblicke für Kostenträger und Plan-Sponsoren, einschließlich prognostizierter Trends und klinischer Perspektiven zu Zell- und Gentherapien sowie Arzneimitteln gegen Alzheimer.
- 14% increase in specialty drug spend and trend, indicating strong market growth
- Growing population of specialty drug utilizers, suggesting expanding market opportunities
- Biosimilars gaining traction, potentially leading to cost savings for payers and patients
- PSG's Artemetrx platform provides valuable data-driven insights for industry stakeholders
- Rising specialty drug costs may lead to increased healthcare expenses for payers and patients
- Continued growth in specialty drug utilization could strain healthcare budgets
- Shift in cost drivers from utilization to cost per claim may indicate pricing pressures
Insights
The Artemetrx State of Specialty Spend and Trend report reveals significant insights for investors in the pharmaceutical and healthcare sectors. The 14% trend in specialty drug spend indicates a robust growth trajectory, potentially benefiting companies focused on specialty pharmaceuticals. This trend, consistently ranging between 10-15% over the years, suggests a stable and growing market.
Of particular interest is the increasing role of cost per claim in driving this trend, alongside claim utilization. This dual-factor growth could translate to higher revenues and potentially improved margins for specialty drug manufacturers. The expanding population of specialty drug users further reinforces the market's growth potential.
Investors should note the rising impact of biosimilars, particularly for Lucentis and Remicade. This trend may pressure margins for original drug manufacturers but presents opportunities for companies developing biosimilars. Humira maintaining its top position in specialty drug spend, despite biosimilar competition, demonstrates the resilience of established brands.
The shift in rankings, with Skyrizi rising from sixth to third place in specialty drug spend, highlights the dynamic nature of this market. This volatility presents both risks and opportunities for pharmaceutical investors, emphasizing the importance of a diversified portfolio in this sector.
The report's findings have significant implications for the broader healthcare market. The continuous growth in specialty drug utilization, without signs of leveling off, suggests a long-term structural shift in healthcare spending patterns. This trend could impact various stakeholders, including insurers, pharmacy benefit managers and healthcare providers.
The increasing complexity of decision-making for plan sponsors and payers, due to factors like high-cost therapies and shifts between medical and pharmacy benefit channels, may create opportunities for companies offering analytics and management solutions in this space.
The report's mention of cell and gene therapies and Alzheimer's Disease drugs as trending topics indicates potential high-growth areas within the specialty drug market. Investors should closely monitor developments in these fields, as they could represent significant market opportunities.
Walmart's sponsorship of this report and its commitment to improving health outcomes through its Specialty Pharmacy division highlights the growing importance of specialty drugs in the retail pharmacy sector. This trend could lead to increased competition among retail pharmacies for specialty drug market share, potentially impacting traditional pharmacy business models.
From a medical research perspective, the continued growth in specialty drug utilization and spend underscores the ongoing innovation in treating complex and chronic conditions. The rise of biosimilars, particularly for drugs like Lucentis and Remicade, indicates a maturing market for certain biologics, potentially improving access and affordability for patients.
The report's focus on cell and gene therapies is particularly noteworthy. These cutting-edge treatments represent a paradigm shift in medicine, offering potential cures for previously untreatable conditions. Their inclusion in the report suggests they are moving from experimental to commercially viable therapies, a significant milestone for the industry.
The mention of Alzheimer's Disease drugs as a trending topic is also crucial. Given the high unmet need in this area, any advancements could have substantial medical and market impact. However, investors should approach this area cautiously, considering the challenges and controversies surrounding recent Alzheimer's drug approvals.
The consistent 10-15% growth in specialty drug spend over the years reflects the ongoing shift towards precision medicine and targeted therapies. This trend is likely to continue as our understanding of disease mechanisms improves, potentially leading to more effective but also more expensive treatments.
Specialty drug spend and trend continue upward momentum with little sign of slowing
The 2024 report found that despite downward pressure by biosimilars and generic specialty drugs, overall specialty drug spend and trend increased in the past year. The
“One important takeaway from this report was that the percentage of members who use specialty drugs continues to rise with no signs of leveling off,” said Renee Rayburg, RPh, VP of Clinical Strategy at PSG. “There are also a handful of external factors influencing changes like more high-cost therapies entering the market, an influx of FDA approvals for branded specialty drugs, and shifts between the medical benefit and pharmacy benefit channels. From our standpoint, there are more variables for plan sponsors and payers to factor into decisions than ever before.”
Biosimilars are continuing to gain traction in the U.S. market, with notably large increases in the market share of the biosimilars for Lucentis and Remicade. Meanwhile, Humira remains the top specialty drug by spend, though Skyrizi rose from sixth in 2022 to third in 2023.
“The trends we are seeing aren’t surprising as much as they are affirming the market shifts we’ve been observing in real time. The PSG team has made considerable strides to stay ahead and account for the market influencers that this year’s report showed,” added Mike Lonergan, RPh, President of PSG.
“Walmart Specialty Pharmacy continues its journey toward improving health outcomes for all, and it starts with ensuring better access to affordable and convenient care,” said Aleata Postell, Group Director of Walmart Specialty Pharmacy. “We are a people-led, omnichannel care provider that remains committed to the communities we serve. The results from this report will further strengthen our ability to innovate and shape the way we prioritize value for our patients and customers.
The 2024 Artemetrx State of Specialty Spend and Trend report reflects PSG’s continued legacy of dedicated client advocacy, offering perspectives on how payers and plan sponsors can transform insights into opportunities. It provides a forecasted trend, which considers new biosimilars and therapies as well as expanded indications for existing drugs. It also offers clinical perspectives on trending topics such as cell and gene therapies and drugs for Alzheimer’s Disease based on data derived from PSG’s Artemetrx platform.
Download the Artemetrx State of Specialty Spend and Trend report and register for the webinar reviewing the key findings here.
About Pharmaceutical Strategies Group (PSG)
Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG is an independent consultant, empowering healthcare payers to manage their pharmacy program better. As a strategic partner, PSG helps clients by providing industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. www.psgconsults.com
About Artemetrx®
Artemetrx is a proprietary SaaS platform developed by Pharmaceutical Strategies Group, an EPIC company. As a revolutionary technology solution integrating pharmacy and medical claims data for specialty drug cost management, Artemetrx provides market-leading specialty drug insights to payers. It delivers unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes. PSG’s innovative drug management solutions, including Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. https://www.psgconsults.com/solutions/data-analytics
About Walmart
Walmart Inc. (NYSE: WMT) is a people-led, tech-powered omnichannel retailer helping people save money and live better — anytime and anywhere — in stores, online, and through their mobile devices. Each week, approximately 255 million customers and members visit more than 10,500 stores and numerous eCommerce websites in 19 countries. With fiscal year 2024 revenue of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725225889/en/
Media
Gregory FCA For Pharmaceutical Strategies Group
Kara Lester
epic@gregoryfca.com
Source: Pharmaceutical Strategies Group
FAQ
What is the key finding of PSG's 2024 Artemetrx State of Specialty Spend and Trend report?
How does the 2024 report's 14% trend compare to previous years?
What are the main drivers of specialty drug trend according to the 2024 report?
How are biosimilars performing in the specialty drug market according to the report?
Which specialty drug remains the top by spend according to the 2024 Artemetrx report?
